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Objective: A bioengineered microporous polycarbonate-siloxane polyurethane graft
has been developed for coronary artery bypass grafting. Biological agents can be
impregnated into its absorbable collagen and hyaluronan microstructure and stable
macrostructure to promote patency. The objective of this study was to examine the
in vivo biological performance and biomechanical characteristics of this graft.
Methods: Three types of graft (3.6-mm internal diameter, 24-mm length) were
manufactured: heparin alone (H) grafts, heparin and sirolimus (HS) grafts, and grafts
without any drug impregnation (C). All H and HS grafts were impregnated with 54 U
of heparin in the microstructure for early elution to prevent acute graft thrombosis and
56 U of heparin in the macrostructure to prevent late thrombosis. In addition to the hep-
arin, the HS graft was impregnated with 2.1mg of sirolimus in themacrostructure for pro-
longed elution to inhibit intimal hyperplasia. All grafts (3.6-mm internal diameter, 24-mm
length) were implanted into the abdominal aortas of rabbits (n5 55). Expanded polyte-
trafluoroethylene grafts (4.0-mm internal diameter, 24-mm length; n5 7) were implanted
as controls. At 1, 3, and 6 months after surgery, the grafts were removed for histologic,
scanning electron microscopic, immunohistochemical, and biomechanical evaluations.
Results: The patency rate was 100% in the H, HS, and C grafts at each time point. Al-
though the expanded polytetrafluoroethylene grafts were patent at 1 and 3 months after
surgery, 1 of 2 grafts (50%) were occluded at 6 months. None of the H or HS grafts had
any stenosis or thrombus. Scanning electronmicroscopic examination proved that endo-
thelial cells propagated smoothly from the anastomotic sites after 6 months in the H and
HS grafts in comparison with the expanded polytetrafluoroethylene grafts, which had
rare endothelialization. Neointima formation was inhibited in the HS graft compared
with the H or C graft at 6 months (1236 126 mm vs 2066 158 mm or 2026 67 mm;
P , .05). In addition, the H, HS, and C grafts had greater cellular infiltration inside
the graft than the expandedpolytetrafluoroethylenegrafts.All grafts except the expanded
polytetrafluoroethylene graft hadmarked neocapillary formation 6months after surgery.
The graft compliance between 80 and 120mmHgwas 6.0%6 2.5% and 6.2%6 0.9%
at 6 months in the H and HS grafts, respectively. The graft macrostructure was un-
changed according to the biomechanical evaluation in the H and HS grafts.
Conclusion: A unique drug-eluting graft had excellent patency throughout the
6 months after implantation. The heparin-sirolimus graft encouraged luminal endothe-
lialization without excessive intimal hyperplasia. This graft performed significantly
better than the expanded polytetrafluoroethylene graft. This graft has the potential
to become an implantable graft for coronary artery bypass grafting.
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C
oronary artery bypass grafting (CABG) is performed
in hundreds of thousands of patients each year in the
United States.1 The most widely used conduits are
autologous internal thoracic arteries, radial arteries, and
saphenous veins, which provide excellent mechanical stabil-
ity and natural antithrombogenicity.2,3 However, these autol-
ogous bypass materials require surgical harvesting, vary in
quality and size, and on occasion have limited availability.
Saphenous vein conduits have the added disadvantage of
relatively poor long-term patency because of degenerative
alterations, such as atherosclerosis or aneurysm formation.4
It has been documented that endothelial cell density on the
vein graft surface is immediately decreased because of arte-
rial pressure-induced stretch and can damage the vessels.5
Because the patency of synthetic small-caliber grafts has
been poor, they have not been practical for CABG. The major
causes of graft failure have been thrombosis and intimal
hyperplasia of the graft. If a synthetic small-caliber graft is
resistant to thrombosis in addition to being biocompatible,
it would have several significant advantages over traditional
autologous grafts. A synthetic graft would have unlimited
availability and consistent quality and patency. Moreover,
the biomechanical uniformity of a synthetic graft could
enable the development of an effective anastomotic device
for minimally invasive surgery.
Our group has developed a small-caliber graft that incor-
porates soluble collagen and hyaluronic acid into the graft
pores. Biological agents can be impregnated into the stable
macrostructure and resorbable microstructure of the graft,creating a 2-tiered drug-release system to promote patency.
The biostability of the graft 1 month after implantation has
been demonstrated.6 The objective of this study was to
examine the in vivo long-term biological performance and
biomechanical characteristics of this graft, and compare
them with those of the present gold-standard expanded
polytetrafluoroethylene (ePTFE) graft.
Materials and Methods
Graft
Experimental grafts with an internal diameter of 3.6 mm were fabri-
cated from a nonresorbable polycarbonate-siloxane polyurethane
using Kensey Nash Corporation’s (Exton, Pa) proprietary foaming
technology (Porous TissueMatrix technology) (Figure 1). Themate-
rial was formed using a tube mold and a controlled thermal cycle to
induce rapid solvent evaporation. This resulted in a highly porous
interconnected scaffold with pore sizes of approximately 25 mm.
The main function of the resultant macrostructure is to provide
most of the mechanical properties for the graft, including compli-
ance, burst strength, and suturability. The microstructure incorpo-
rated into the pores of the graft was resorbable bovine hide-derived
collagen (Kensey Nash) and hyaluronic acid (LifeCore Biomedical,
Chaska,Minn). The purposes of themicrostructure are to provide the
biological properties for proper cell attachment and proliferation,
deliver a biological additive over a prolonged time period, and
prevent leakage of fluid through the porous macrostructure.
Moreover, drugs were incorporated into the graft wall during the
manufacturing process. Heparin (Celsus Laboratories, Cincinnati,
OH) was added to both the macrostructure and microstructure raw
materials before device fabrication, and sirolimus (Chemwerth,
Woodbridge, Conn) was also added to the macrostructure raw mate-
rial before fabrication. Biological agents were incorporated into the
vascular grafts during manufacturing to prevent short and long-
term thrombosis, as well as chronic smooth muscle cell hyperplasia.
In this study, 3 types of grafts (3.6-mm internal diameter, 24-mm
length) were manufactured: heparin alone (H) grafts, heparin and
sirolimus (HS) grafts, and grafts without any drug incorporation
as a control (C). All H and HS grafts were manufactured with 40Figure 1. Explanted H and HS grafts at 6 months. There was no stenosis at the anastomotic sites and center of the
grafts. H, Heparin alone; HS, heparin 1 sirolimus.
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structure for early elution to prevent acute graft thrombosis and
100 U of heparin in the macrostructure for prevention of late throm-
bosis. In addition to the heparin incorporation, the HS graft was
manufactured with 2.1 mg of sirolimus (Chemwerth) in the macro-
structure for prolonged elution to inhibit intimal hyperplasia. All
grafts were terminally sterilized by exposure to gamma radiation
at a minimum dose of 25 kGy. The data were compared with the
ePTFE graft (Gore-Tex Vascular Graft Configured for Pediatric
Shunt; WL Gore & Associates, Inc, Flagstaff, Ariz) with an internal
diameter of 4.0 mm and a length of 24 mm.
Surgical Procedure
All animals received humane care in compliance with the ‘‘Princi-
ples of Laboratory Animal Care,’’ formulated by the National Soci-
ety for Medical Research, and the ‘‘Guide for the Care and Use of
Laboratory Animals,’’ prepared by the National Academy of Sci-
ence and published by the National Institutes of Health (Publication
86-23, revised 1985). In addition, the Animal Studies Committee of
the Washington University School of Medicine approved this study
protocol.
Sixty-two New ZealandWhite rabbits weighing between 3 and 4
kg were used randomly in this study. All animals were anesthetized
with ketamine (70 mg/kg) intramuscularly, intubated with a 3-mm
cuffed endotracheal tube, and mechanically ventilated with
a pressure-controlled ventilator. An adequate level of anesthesia
was maintained by inhaled isoflurane (1%–3%). A limb-lead
electrocardiogram was monitored. A central ear artery catheter
was inserted to continuously monitor systemic arterial pressure.
Arterial blood samples were drawn every 30 minutes to determine
arterial oxygen tension, acid-base balance, and electrolyte levels.
Ringer’s lactate solution was infused continuously, and sodium
bicarbonate, potassium chloride, and calcium chloride were supple-
mented to maintain pH and electrolytes within normal values.
Enrofloxacin (5 mg/kg) was administrated preoperatively to reduce
the risk of infection.
After a midline abdominal incision, the intestines were dis-
placed to the right side and covered with moistened gauze. The in-
frarenal aorta was carefully dissected from the surrounding tissue.
The lumbar arterial branches were spared to avoid spinal cord
ischemia. Intravenous heparin (200 U/kg) was administered. The
abdominal aorta was clamped with microapproximator clamps
between the lumbar branches and transected. The H, HS, C, or
ePTFE grafts were anastomosed to the aorta in an end-to-end fash-
ion with a continuous 7-0 polypropylene suture. The total anasto-
motic time was less than 30 minutes in every animal (22 6 4
minutes). Blood flow was measured with an ultrasonic flow probe
(Transonic System Inc, Ithaca, NY) proximally and distally. The
abdominal incision was closed. The animals received analgesia
(buprenorphine 0.3–0.5 mg/kg) and antibiotic (enrofloxacin 5
mg/kg) treatments subcutaneously twice daily for 2 days after sur-
gery. Postoperative antiplatelet therapy (aspirin 15 mg/kg) was
administered daily.
At 1, 3, and 6 months after surgery, the animals were anesthe-
tized again with intramuscular ketamine (70 mg/kg) (H grafts:
N 5 9, 9, and 9; HS grafts: N 5 7, 9, and 9; C grafts: N 5 0, 0,
and 3; and ePTFE grafts: N 5 2, 3, and 2 at 1, 3, and 6 months,
respectively). The abdominal incision was reopened. The surgical
site was examined for adhesions, fibrosis, hematoma, or arteriove-The Journal of Thornous fistula. Blood flow at the proximal and distal anastomoses
was measured with an ultrasonic flow probe. The animal was
euthanized, and the graft was carefully removed for biomechanical,
histologic, and immunohistochemical evaluations.
Biomechanical Characterization
Graft Compliance Test. The graft and approximately 1 cm of
intact aorta proximally and distally were dissected. The graft was
secured to a customized fixture designed to pressurize the sample
while holding it at a set length. The setup contained a pressure gauge
(Digimano 1000, Netech, NY) inserted in-line downstream from the
graft. The system was pressurized by injecting saline in 0.02-mL
boluses using a calibrated repeat pipettor (Repeater Plus, Eppendorf,
NY) placed upstream from the graft. The internal radius was
calculated from the volume assuming an incompressible fluid and
a length that remained constant. Radial compliance was reported
as the percent change in calculated radius per change in measured
pressure.
Graft Tensile Strength Test. The graft and approximately 1 cm
of intact aorta proximally and distally were dissected. Two
5-mm–wide ‘‘rings’’ were cut from the middle of the graft for tensile
testing. Graft outer diameter, length, and thickness were measured.
Two dowel pins were inserted into the ring and secured with a hold-
ing fixture to a mechanical test stand (Model TCD200, Chatillon,
Largo, Fla) with a 2-lb load cell (Model DFGS 2, Chatillon). The
pins were then pulled apart at a rate of 50 mm/min while measuring
tensile force versus displacement. Ultimate tensile strength was
calculated as ultimate tensile strength 5 max load/(2 3 thickness
3 length).
Graft Anastomotic Strength Test. After the ‘‘rings’’ were re-
moved from the center of the graft for tensile strength testing, the re-
maining ends of the graft/aorta interface were tested to determine the
strength of the anastomosis. Samples were clamped on each end so
that 2 mm of graft and 2 mm of aorta were exposed. The grips were
secured to a mechanical test stand (Model TCD200, Chatillon) with
a 2-lb load cell (Model DFGS 2, Chatillon). Samples were pulled
apart at 2 inches per minute, and the peak tensile force was recorded.
Histologic and Immunohistochemical Evaluations
Histology. The graft and approximately 1 cm of intact aorta
proximally and distally were dissected. The specimen was fixed in
10% buffered formalin, dehydrated in a graded series of ethanol,
and embedded in paraffin. Longitudinal and transverse sections
were obtained along the length of the graft for tissue processing,
and the paraffin blocks were sectioned at 4 to 6 mm and mounted
on a charged glass slide. Slides were stained with hematoxylin-
eosin, and Movat pentachrome. Graft patency, neointima formation,
endothelialization of the graft, and tissue ingrowth and angiogenesis
in the graft wall were examined histologically.
Immunohistochemistry. Dewaxed paraffin sections were treated
with 0.3% hydrogen peroxide to inactivate endogenous peroxidases.
The sections were then immersed in protein-free block (Dako, Car-
pinteria, Calif) to block nonspecific binding of primary antibodies.
Sections were incubated for 1 hour at room temperature with primary
antibodies against human smooth muscle beta-actin (clone HHF35,
dilution 1:20, Enzo, Farmingdale, NY), the macrophage marker
Ram-11 (dilution 1:200, Dako), and a purified polyclonal antibody
to von Willebrand factor (dilution 1:2000, Strategic Biosolutions,
Newark, Del).acic and Cardiovascular Surgery c Volume 135, Number 6 1239
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link antibody from a peroxidase-based kit (LSAB, Dako). Positive
staining (rose reaction product) was visualized using a 3-amino-
9-ethylcarbazole substrate-chromogen system; the sections were
counterstained with Gill’s hematoxylin.
Scoring. Luminal surface fibrin/platelet aggregation, endotheli-
alization, and cellular infiltration of the grafts were scored from
0 to 4. Grade 0 was defined as no appreciable fibrin/platelet aggre-
gation or cellular infiltration present. Grade 1 (minimal) denoted
fibrin/platelet aggregation, the presence of cellular infiltration less
than one fourth the thickness of the graft conduit wall, or endotheli-
alization of one quarter of the cross-sectional luminal surface. Grade
2 (mild) indicated fibrin/platelet aggregation or the presence of
cellular infiltration up to or equal to one half of the thickness of
the graft conduit wall or endothelialization of one half of the
cross-sectional luminal surface. Grade 3 (moderate) signified
fibrin/platelet aggregation or the presence of cellular infiltration up
to or equal to three quarters of the thickness of the graft conduit
wall or endothelialization of three quarters of the cross-sectional
luminal surface. Grade 4 (severe/marked) was identified by fibrin/
platelet aggregation, the presence of cellular infiltration throughout
the full thickness of the graft conduit wall, or complete endothelial-
ization of the cross-sectional luminal surface. The histologic index
was calculated by dividing the sum of the grade by the number of
sample grafts (grade/N) at the anastomotic sites and center of the
grafts.
Scanning Electron Microscopy Evaluation
For 1 of the grafts in each group at each time point, scanning electron
microscopy (SEM) imaging was performed. SEM was used to eval-
uate the presence of thrombi, endothelial coverage, and endothelial
maturity. Before processing, the specimens were bisected longitudi-
nally to expose the luminal surface and photographed. Specimens
were rinsed in 0.1 mmol/L sodium cacodylate buffer (pH 7.2) and
then post-fixed in 1% osmium tetroxide for 30 minutes. Specimens
were dehydrated in a graded series of ethanol. After critical point
drying, the tissue was mounted and sputter-coated with gold, and
specimens were visualized using a Hitachi scanning electron
microscope (Hitachi Medical, Tokyo Japan). The percentage of
endothelium was based on a visual estimate.
Statistical Analysis
Continuous values are expressed as mean 6 1 standard deviation.
Comparisons were made by Student t test assuming unpaired data.
Results
All rabbits in groups H, HS, C, and ePTFE survived after
surgery. Paraplegia was not observed in any animal during
the postoperative period.
Rheologic Data and Graft Morphology
The patency rate was 100% in the H, HS, and C grafts at each
time point. Although the ePTFE graft was patent at 1 and
3 months after surgery, 50% of the grafts were occluded at
6 months. There were no significant differences in blood
flow at the proximal and distal anastomoses after the initial
implantation and at the end of study in any group (Table 1).1240 The Journal of Thoracic and Cardiovascular Surgery c JAlthough none of the H, HS, and C grafts had any throm-
bus or stenosis inside the graft, 2 of 3 ePTFE grafts at
3 months had thrombus, which was not occlusive. One of
2 ePTFE grafts at 6 months was completely occluded by
thrombus. Although all grafts were covered by an adhesion
capsule, there was no stenosis observed histologically at
the proximal or distal anastomoses (Figure 1). There were
no apparent changes in the graft, including dilatation,
collapse, dehiscence, or aneurysm formation, during the
6-month postoperative period. There was no bleeding from
the grafts and no arteriovenous fistulae formation.
Biomechanical Characterization
Graft Compliance. The graft compliance data are shown
in Figure 2, A. The preoperative graft compliances between
80 and 120 mm Hg of the H and HS grafts were
7.4% 6 2.4% and 8.3% 6 0.4%, respectively (P 5 .6932).
The postoperative compliances of the H graft were 8.5%
6 1.6%, 4.4% 6 1.0%, and 6.0% 6 2.5% at 1, 3, and 6
months after surgery, respectively. The postoperative
compliances of the HS graft were 11.6% 6 0.2%, 5.1%
6 1.3%, and 6.2% 6 0.9% at 1, 3, and 6 months after
surgery, respectively. There were no significant differences
in the graft compliance over time.
Graft Tensile Strength. The tensile strengths of the H and
HS grafts were 967 6 200 kPa and 794 6 70 kPa preopera-
tively (P 5 .0371, Figure 2, B). The postoperative tensile
strength of the HS graft was significantly greater than that
of the H graft at 1 and 3 months after surgery (P 5 .0013
and .0053, respectively). At 6 months, there was no signifi-
cant difference in the tensile strength between H and HS
grafts (P5 .1671). The tensile strength of the rabbit descend-
ing thoracic aorta was measured to be 1410 6 310 kPa.
Although there was no significant difference in the tensile
strength between the HS graft at 6 months and the descending
thoracic aorta (P 5 .1290), the H graft strength at 6 months
was significantly lower than that of the descending thoracic
aorta (P 5 .0092).
Anastomotic Strength. The proximal and distal anasto-
motic strengths of the H graft were significantly greater
than those of the HS graft at 1 month after surgery
(P 5 .0002 and .0033, respectively; Figure 3). However,
TABLE 1. Blood flow at the proximal and distal
anastomosis
Graft implantation End of study
Graft Proximal Distal P value Proximal Distal P value
H 51 6 23 48 6 22 .6206 56 6 24 50 6 21 .3402
HS 48 6 25 43 6 21 .4664 64 6 20 59 6 18 .3075
C 35 6 4 32 6 9 .6367 56 6 27 55 6 27 .9660
ePTFE 41 6 16 35 6 16 .5138 46 6 24 33 6 19 .2831
ePTFE, Expanded polytetrafluoroethylene.une 2008
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between the H and HS grafts at later time periods. The prox-
imal anastomotic strengths of the HS grafts increased as time
advanced.
Histologic Characterization
Although 1 ePTFE graft was occluded at 6 months after sur-
gery, all H, HS, and C grafts were patent and had no stenoses
histologically during the 6-month follow-up (Figure 4). In
the early postoperative period (1–3 months), all grafts were
mildly covered with luminal surface fibrin (Figure 5, A). The
graft wall was predominantly infiltrated by red blood cells
and aggregates of platelets with some leukocytes. Less luminal
fibrin/platelet formationwas found in theH,HS, andCgrafts at
6 months after surgery when compared with the ePTFE grafts.
There was a mild amount of neointima formation at 3 to 6
months after surgery in the H and C grafts (Figure 5, A). In the
HS graft, neointima formation was inhibited more than the H
or C graft for the first 6 months (Figure 6). There was no
excessive intimal hyperplasia in any HS grafts. The average
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Figure 2. A, Preoperative and postoperative graft compliance. B,
Preoperative and postoperative graft tensile strength. *P < .05.
**P < .01. H, Heparin alone; HS, heparin 1 sirolimus.The Journal of Thorneointimal thickness at the region of anastomotic sites at
6 months was 206 6 158 mm in the H grafts and 123 6
126 mm in the HS grafts (P5 .0288). Although the neointima
thickness serially increased in the HS graft after surgery dur-
ing 3 months, neointima hyperplasia was inhibited in the HS
graft after 3 months. There was less neointima in the ePTFE
graft at all time points. The neointimal thickness of the
ePTFE was 28 6 14 mm at 6 months.
Serial changes in the endothelialization of the grafts are
shown in Figure 5, B. At 1 month, the H graft had a layer
of spindle-shaped, immature mesenchymal cells covering
the anastomotic site from the native aorta (grade 1). Although
the HS grafts showed no endothelialization at the anasto-
motic sites and the center of the graft at 1 month, the HS
grafts showed considerable endothelialization at the 3-month
time point. Despite the increased endothelialization score, the
scores were slightly lower than that of the H graft. The H, HS,
and C grafts had significant endothelialization at the anasto-
motic sites and center of the graft at 6 months. The ePTFE
graft barely had any endothelialization at 6 months.
The H and ePTFE grafts had significant cellular infiltra-
tion inside the grafts 1 month after surgery (Figure 5, B).
The resorbable microstructure in the H and HS grafts consist-
ing of bovine-derived collagen was completely replaced by
the autologous tissue. In the HS graft, although autologous
tissue infiltrated mildly at 1 month, the score of the cellular
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A
CDFigure 4. Histology and immunohistochemical findings of the grafts at 6 months. Normal-appearing endothelial cells
were aligned with the blood flow. The endothelial cell layer is smooth from the native aorta to the graft in H, HS, and
C grafts. Therewere less endothelial cells in the ePTFE graft. Moderate cellular infiltrationwas observed in the graft
wall in the H and HS grafts (upper: Movat stain 403). A layer of endothelial cells is shown on inside of the H, HS, and
C grafts. Moderate neocapillary formation is shown in the graft wall in the H, HS, and C grafts (lower: vonWillebrand
factor stain 1003, red dots in the graft wall). ePTFE, Expanded polytetrafluoroethylene; H, heparin alone; HS, heparin1
sirolimus.infiltration was serially increasing at anastomotic sites and
center of the graft after 3 months. A great deal of neocapillary
formation was observed in the graft wall in the H, HS, and C
grafts. Although there were blood cells inside the neocapilla-
ries in the H, HS, and C grafts, the ePTFE graft had no
neocapillary formation inside the graft during 6 months.
Scanning Electron Microscopy Findings
The lumens of the H and HS grafts were completely covered
by a layer of endothelial cells at 6 months (Figure 7). The HS
graft had a smoother and tighter endothelial cell layer com-
pared with the other grafts. Although the endothelial cells
covered the entire inside of the C graft, the layer of endothelial
cells of the C graft was not smooth or regular. In the ePTFE
graft, there was minimal endothelialization at 6 months.
A luminal fibrin/platelet sheet covered the ePTFE graft wall.
Discussion
This study examined the in vivo biological and mechanical
performance of a novel bioengineered small-caliber vascular
graft during a period of 6 months. The graft enabled the
controlled release of biological agents to theoretically inhibit
acute and chronic thrombus formation, as well as intimal
hyperplasia. Heparin was embedded in the microstructure
of the graft for early elution. Heparin and sirolimus were
incorporated into the macrostructure of the graft for late1242 The Journal of Thoracic and Cardiovascular Surgery c Juelution. Although both the H and HS grafts had a 100%
patency rate during the 6 months after surgery, the HS graft
showed less neointima formation than the H graft. A thin
neointima, which included elongated endothelial cells,
extended smoothly into the graft wall without any intimal
hyperplasia in the HS graft 6 months after implantation.
The H and HS grafts incorporated either heparin or hepa-
rin and sirolimus in the graft wall. In a previous study from
our laboratory, it was shown that heparin had eluted from
the graft microstructure during the first month postopera-
tively.6 In this study, the microstructure of the graft was
replaced by autologous tissue after 1 month. It has been pro-
posed that heparin eluted from the graft wall could prevent
acute thrombus.7,8 Although our study showed similar histol-
ogy between the grafts with (H) and without (C) heparin, the
SEM evaluation revealed that there was a considerable differ-
ence in the degree of endothelialization between the H and C
grafts. The C graft had rougher endothelial layers than the H
graft at 6 months. Heparin and sirolimus impregnated in the
macrostructure played a more important role in endotheliali-
zation and neointima thickening than heparin alone. Siroli-
mus has been reported to inhibit the proliferation of smooth
muscle cells and prevent neointima thickening.9-12 Our study
supported this hypothesis. The HS graft had a complete and
smooth layer of endothelial cells and less neointima forma-
tion compared with the H or C graft in this study.ne 2008
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Figure 5. Serial changes in neointima
formation, luminal fibrin/platelet forma-
tion, endothelialization, and cellular in-
filtration at the anastomotic sites and
center of the grafts. The histologic index
was calculated by dividing the sum
of the grade by the number of sample
grafts (grade/n). ePTFE, Expanded poly-
tetrafluoroethylene; H, heparin alone;
HS, heparin1 sirolimus.Synthetic grafts have been used for revascularization in
patients who have limited autologous graft materials avail-
able. Satisfactory synthetic materials have not been devel-
oped for CABG because of their poor long-term patency
rates. Although Dacron and ePTFE grafts have been used
successfully in peripheral revascularization cases, these
small-caliber vascular grafts have failed for coronary revas-
cularization.13 Dacron grafts suffer from thrombosis and
neointimal proliferation. ePTFE grafts also have had poorThe Journal of Thorpatency rates because of surface thrombogenicity.14 It has
been described that endothelial cell-seeded grafts could
decrease thrombogenicity and intimal hyperplasia.15-17
However, cell-seeded grafts are not practical for CABG cases
because of the complex, time-consuming, and costly
manufacturing process.
In this study, the ePTFE graft had less endothelialization
and moderate luminal fibrin/platelet formation at 6 months.
The SEM evaluation showed that fibrin and platelets coveredacic and Cardiovascular Surgery c Volume 135, Number 6 1243
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alone; HS, heparin 1 sirolimus.the inside of the ePTFE graft wall instead of endothelial cells
at 6 months. Less endothelialization likely caused 1 graft oc-
clusion of the graft 6 months after surgery. Smooth endothe-
lial layers are prerequisite for good long-term patency.18 The
HS graft had the smoothest endothelial layers inside the graft
in all grafts.
The biomechanical tests established the biostability of
the grafts under arterial blood flow conditions. None of
the H, HS, and C grafts showed any aneurysm formation,
dilatation, or structural collapse during the 6-month postop-
erative period. Fresh porcine carotid artery compliance was
9.4% 6 2.2%.6 Human saphenous vein and ePTFE graft
compliances over a pulse pressure of 40 mm Hg are known
to be 2.0% and 1.0%, respectively.19,20 Significant changes
in the graft compliance in the H and HS grafts were not
seen during 6 months. The graft compliances of the H
and HS graft were always greater than that of human saphe-
nous vein or ePTFE grafts. The tensile strength of the native
descending thoracic aorta of rabbits was 1436 6 450 kPa,
as reported in our previous study.6 There were no signifi-
cant changes in tensile strength of the H and HS grafts
over time and at 6 months. They were not statistically
different from each other. In general, the tensile strength,
particularly of the HS graft, approximated that of the native
aorta.
By histologic and immunohistochemical evaluations,
there was significant neocapillary formation in the walls of
the H, HS, and C grafts 1 month after surgery. However, theFigure 7. SEM findings. Endothelial
cells covered the inside of the H and
HS grafts. The layer of endothelial cells
of the HS graft was smoother than that
of the H graft. The C graft had rough en-
dothelial cells. The ePTFE graft had less
endothelial cells and marked fibrin/
platelet deposition. ePTFE, Expanded
polytetrafluoroethylene; H, heparin
alone; HS, heparin 1 sirolimus.
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CDePTFE graft had no neocapillary formation even 6 months
after surgery. If synthetic vascular grafts are used for
CABG, the length of the graft may need to be long. Endothe-
lial cells can migrate into the graft from the (1) anastomotic
sites, (2) circulating blood, and (3) neocapillaries inside the
graft.21 It would take a long time to extend endothelial cells
from the anastomotic sites in a long graft for clinical applica-
tion. In addition to the extension from anastomotic sites and
the contribution from the circulating blood, migration from
the neocapillaries could carry endothelial cells to the center
of the graft. The neocapillary formation may be an advantage
to encourage endothelialization for synthetic vascular grafts.
Conclusions
A unique bioengineered microporous drug-eluting graft had
excellent patency throughout the 6months after implantation.
Biological agents, heparin and sirolimus, were impregnated
into the graft and encouraged luminal endothelialization
and neointimal formation. This graft has the potential to
become an implantable graft for CABG.
This study was a 6-month evaluation of a novel bioengi-
neered synthetic small-caliber graft involving 62 rabbits.
Because grafts were examined for histology and biomechan-
ical properties at several different time points, the number of
implanted grafts at each time point was small. However, data
of each time point were similar and consistent. The C grafts
were evaluated at only 6 months after surgery to be compared
with the H, HS, and ePTFE grafts. This is a preliminary study
in a rabbit aortic model. A longer term study will be needed to
evaluate the chronic efficacy of the eluted drugs. A large
animal coronary bypass graft model is needed to establish
clinical feasibility.
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Discussion
Dr Robert Poston (Baltimore, Md). Why does sirolimus affect en-
dothelialization in stents but not in your grafts? What is the dif-
ference there? It is pretty well known that sirolimus reduces
re-endothelialization on top of an intracoronary stent, but it did
appear to have the same affect on the conduits in your research.
Dr Ishii.Regarding the endothelialization, in the SEMvariations
we can see it occurring beautifully inside the graft wall. When com-
pared with a non-sirolimus graft, sirolimus might therefore facilitate
good endothelialization. However, although both heparin and hepa-
rin-sirolimus grafts had a 100% patency rate during the 6 months
after surgery, the heparin-sirolimus grafts showed less neointima
formation than the heparin grafts.
Dr Poston.Maybe it is not just understood how that works. The
second question is related to your model. Themain concern that peo-
ple have regarding the use of small prosthetic grafts as bypass con-
duit for the heart would be acute thrombosis. Your control grafts in
your model didn’t acutely thrombose, even the PTFE graft without
heparin. So do you think that this model is adequately testing the key
limitation of these grafts?ic and Cardiovascular Surgery c Volume 135, Number 6 1245
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CDDr Ishii. Actually you are right. This is a good question,
Dr Poston. We didn’t see any acute thrombosis in either the con-
trol grafts without drugs or in the heparin and sirolimus grafts.
However, half of the ePTFE grafts in this study occluded during
the 6 months after surgery. When compared with our micropo-
rous polyurethane grafts, the ePTFE grafts showed less endothe-
lialization. As I showed you with the SEM data, out of all the
grafts the heparin-sirolimus grafts had the most beautiful layer
of endothelial cells.
Dr Beat H. Walpoth (Geneva, Switzerland). I think what are
you doing is a bit controversial. Our series on rapamycin-treated
grafts was published in the European Journal of Cardiothoracic
Surgery in 2000, and we showed that there is a significant reduc-
tion of intimal hyperplasia. I think your data were not significant.
In addition, we had no endothelialization; we had much more
thrombus formation. So this goes along with what is now seen
in the drugeluting stents. In medicine, everything is a question
of dosage. I am not sure if eventually your dosage was not potent1246 The Journal of Thoracic and Cardiovascular Surgery c Juenough to achieve this goal. Anyhow, they are some interesting
results.
Dr Valavanur Subramanian (New York, NY). Just a brief com-
ment to bring you up to date. There are drug-eluting wraps around
the grafts that have already been in clinical use in arteriovenous fis-
tula. Our colleagues in endovascular cardiology have now taken
a different form of wrap around the distal anastomosis with
a PTFE or saphenous vein graft. The first feasibility trial will soon
be done in coronary bypass grafts pretty, and the 6-month patency
in the arteriovenous fistula has been excellent. So there is already
a clinical movement on this approach.
Dr Cliff Choong (Cambridge, United Kingdom). Do you have
any data on longer-term results, and are you planning to do any
long-term experimental studies?
Dr Ishii. Actually this is just a preliminary rabbit model. We
don’t have any longer-term data yet. As you mentioned, we should
do a larger animal study and longer-term study before attempting
any clinical applications. We are planning that now.ne 2008
